hotspot -WSS

hotspot

author：Wikipedia 2025-09-27 19:38:05 - browse：5

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Kristina Burow of ARCH Venture Partners shares her next big bets STAT

focus

WSS

7 of the most gruesome medical devices in history

FDA official pushes for dedicated emerging pathogens team

Russian special forces kill a gunman who broke into a private house near Moscow

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

FogPharma raises $145 million in rare Series E round

New rules on organ donation and transplantation 'will bring chaos'

explore

hotspot

hotspot

Heart attack and stroke risk calculators need revising

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Tori Bowie and the unacceptable rates of Black maternal death

New rules on organ donation and transplantation 'will bring chaos'

As demand for Covid shots wanes, Moderna seeks its next success

Court strikes down limits on filming of police in Arizona

At least 13 dead in Texas as scorching temps continue

FDA official pushes for dedicated emerging pathogens team

Hollywood unions extend contract negotiations for actors

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

explore

FDA does about

Our daughter's deadly disease: trisomy 18. We wanted to protect her

7 of the most gruesome medical devices in history

Obesity now affects over 1 billion people worldwide, study finds

Why an extreme heat and wildfire smoke combination can be so dangerous

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

hotspot

focus

Wikipedia

entertainment